A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy With DBV712 250 mcg in 1-through 3-year-old Children With Peanut Allergy

The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.

Start Date24 Jun 2025

Sponsor / Collaborator

DBV Technologies SA

NCT05741476

/ Active, not recruitingPhase 3

A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 Μg in 4-7-year-old Children with Peanut Allergy (VITESSE)

The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.

Start Date21 Feb 2023

Sponsor / Collaborator

DBV Technologies SA

EUCTR2018-003323-10-DE

/ Unknown statusPhase 3

EPITOPE OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM CLINICAL BENEFIT AND SAFETY OF DBV712 IN PEANUT-ALLERGIC CHILDREN (EPOPEX) - EPOPEX

Start Date11 Feb 2021

Sponsor / Collaborator-

100 Clinical Results associated with Peanut allergy immunotherapy(DBV Technologies SA)

100 Translational Medicine associated with Peanut allergy immunotherapy(DBV Technologies SA)

100 Patents (Medical) associated with Peanut allergy immunotherapy(DBV Technologies SA)

Literatures (Medical) associated with Peanut allergy immunotherapy(DBV Technologies SA)

01 May 2025·Journal of Allergy and Clinical Immunology-In Practice

Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)

Article

Author: Siri, Dareen ; Petroni, Daniel ; Sussman, Gordon ; Sindher, Sayantani B ; Wood, Robert ; Lanser, Bruce J ; Kim, Edwin H ; Bois, Timothée ; Chan, Edmond S ; Brown-Whitehorn, Terri F ; Sher, Lawrence D ; Yang, William H ; Bird, J Andrew ; Rupp, Ned ; Chinthrajah, R Sharon ; Berger, William E ; Shreffler, Wayne G ; Scurlock, Amy M ; Bee, Katharine J ; Fineman, Stanley M ; Oriel, Roxanne C ; Fleischer, David M ; Gagnon, Rémi ; Chong, Hey J ; Anvari, Sara ; Sampson, Hugh A ; Bégin, Philippe ; Green, Todd D ; Gonzalez-Reyes, Erika ; Mehta, Hemalini ; Campbell, Dianne E ; Schneider, Lynda C ; Pongracic, Jacqueline A ; MacGinnitie, Andrew

BACKGROUND:

Owing to limited treatment options for peanut allergy, patients remain at risk for allergic reactions due to accidental exposure. Epicutaneous immunotherapy (EPIT) is a novel treatment being investigated for peanut allergy.

OBJECTIVE:

This study assessed long-term safety of EPIT with VIASKIN peanut patch 250 μg (VP250) via an open-label extension of the REAL Life Use and Safety of EPIT (REALISE) trial.

METHODS:

REALISE was a phase 3 trial in peanut-allergic children aged 4 through 11 years that included a 6-month, randomized, double-blind, placebo-controlled treatment phase, followed by an open-label, single-arm, active treatment period for up to 36 months.

RESULTS:

Of the 392 participants (male 54.8%; median age 7.2 y) who received at least 1 dose of treatment, 77.8% completed the 36-month active treatment. Mean adherence to treatment was high at 96.4%. Most participants (98.7%) experienced at least 1 treatment-emergent adverse event (TEAE); the majority were mild or moderate and decreased in frequency and severity over time. Most participants (94.6%) experienced at least 1 treatment-related TEAE. Local skin reactions were the most common treatment-related TEAE with the incidence decreasing from year 1 (87.8%) to year 3 (19.2%). Serious treatment-related TEAEs were reported in 2 participants. No specific safety signals were identified in the 14 participants enrolled with a history of severe anaphylaxis (Anaphylaxis Staging System grade 3).

CONCLUSION:

Consistent with previous phase 3 studies, long-term EPIT with VIASKIN peanut patch 250 μg was well tolerated with high adherence in peanut-allergic children aged 4 through 11 years (clinicaltrials.gov; NCT: NCT02916446).

01 Apr 2025·PEDIATRIC ALLERGY AND IMMUNOLOGY

Epicutaneous immunotherapy: A review of safety and efficacy

Review

Author: Greenhawt, Matthew ; Anagnostou, Aikaterini

Abstract:

Epcutaneous immunotherapy (EPIT) is a novel, non‐oral route of allergen immunotherapy, utilizing the skin and its robust density of epidermal Langerhans cells (LC) for antigen presentation. This space is non‐vascularized and impermeable, which limits allergen exposure into the bloodstream but preserves antigen presentation to regional lymph nodes to generate gut‐homing regulatory T cells. The EPIT patch utilizes natural water loss from the skin to absorb electrosprayed allergen through condensation. EPIT represents an alternative, non‐oral route of immunotherapy for food allergy, with good efficacy and strong safety profiles across multiple phase 2 and 3 studies for milk and peanut. Efficacy appears the best in very young children (1–3 years old), which has been shown to continue to enhance with extended treatment duration up to 36 months. Efficacy in slightly older children ages 4–11 years of age is less clear, but appears to be better in children ages 4–7 years of age. In clinical trials of milk and peanut EPIT, most subjects experienced adverse effects, mainly mild‐to‐moderate skin reactions localized around the patch placement site, which improve with continued duration of wear. Rates of treatment‐related anaphylaxis have been very low across all studies and ages, ranging from 1.6% to 4%, and were lowest in the infant and toddler population. While further studies of safety (1‐ to 3‐year‐olds) and efficacy (4‐ to 7‐year‐olds) are ongoing, EPIT is a potentially valuable addition to the current landscape of food allergy therapies, in particular for infants and toddlers where families may be seeking a non‐oral route of treatment.image

01 Mar 2025·Clinical and Translational Allergy

Epicutaneous immunotherapy for food allergy: A systematic review and meta‐analysis

Review

Author: Lee, Bohee ; Kuitunen, Ilari ; Csonka, Péter

Abstract:

Background:

Food allergies pose a global healthcare challenge, underscoring the need for effective interventions. This study evaluated the efficacy and safety of epicutaneous immunotherapy (EPIT) for food allergen desensitisation.

Methods:

We conducted a systematic review of randomised controlled trials by searching Ovid EMBASE, PubMed and Scopus in April 2024. Using a random‐effects meta‐analysis, we evaluated the clinical effectiveness and harms of EPIT, reporting results as risk ratios with 95% confidence intervals (CI).

Results:

After screening 460 abstracts and 35 full reports, 11 were included: nine on peanuts and two on cow's milk (CM). Peanut EPIT had a 51.2% treatment response versus 22.4% for placebo (RR 2.16, CI 1.49–3.12; four studies; moderate certainty). The RR for milk EPIT response rate was 1.78 (CI 1.06–3.00; one study). Five peanut studies (1396 patients) reported EPIT‐related adverse events (RR 1.39, CI 0.94–2.05; low certainty).

Conclusions:

EPIT offers a moderate treatment response with a favourable safety profile and significant improvements in quality of life. Current knowledge of EPIT remains limited, with evidence confined to peanut and CM allergies. There is a lack of research on sustained unresponsiveness achieved through food EPIT.

News (Medical) associated with Peanut allergy immunotherapy(DBV Technologies SA)

30 Oct 2025

·dbv-technologies.com

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company’s shareholders at the next annual meeting of shareholders. Dr. Lee will also serve as a member of the Compensation Committee of the Board. With this addition, the Company’s Board comprises ten directors. “We are pleased to welcome Philina Lee as a new independent director to the Board,” said Michel de Rosen, Chairman of the Board. “Philina’s extensive experience building successful biopharmaceutical organizations and commercializing pharmaceutical products will add tremendous value as the Company moves closer to potential commercialization.” Dr. Lee joins DBV following a distinguished tenure at Blueprint Medicines where she progressed through increasingly senior roles, culminating in her leadership of the company’s commercial organization as Chief Commercial Officer, overseeing the successful launch and growth of AYVAKIT®. She previously was on the Board of Directors at Fusion Pharmaceuticals, where she served on both the Nomination and Governance Committee and the Research and Development Committee. “I am honored to join DBV’s Board at such a pivotal time for the Company, as it continues to advance VIASKIN® Peanut for children and toddlers with peanut allergy,” said Dr. Lee. “I look forward to serving on the Compensation Committee and contributing to DBV’s growth and success.” About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). VIASKIN is a registered trademark of DBV Technologies. Investor Contact Katie MatthewsDBV Technologieskatie.matthews@dbv-technologies.com Media ContactBrett WhelanDBV Technologiesbrett.whelan@dbv-technologies.com Attachment

Executive ChangeImmunotherapy

28 Oct 2025

·dbv-technologies.com

DBV Technologies Reports Third Quarter 2025 Financial Results

Châtillon, France, October 28, 2025 DBV Technologies Reports Third Quarter 2025 Financial Results DBV closes Q3 2025 with a cash and cash equivalents balance of $69.8 million, taking cash runway into the third quarter of 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company (the “Company”), reported financial results for the third quarter of 2025. The quarterly and nine months unaudited financial statements were approved by the Board of Directors on October 28, 2025. Financial Highlights for the third quarter ended September 30, 2025The Company’s unaudited interim condensed consolidated financial statements for the nine months ended September 30, 2025, are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Operating IncomeThe increase in Research tax credit during the three and the nine months ended September 30, 2025, is primarily due to the fact that more eligible activities have been carried out in the period, including the related costs of the FAREVA platform. Operating ExpensesOperating expenses amounted to $107.0 million for the nine months ended September 30, 2025, compared with $96.4 million for the nine months ended September 30, 2024, an increase by $10.6 million driven mostly by the launch of the COMFORT Toddlers supplemental safety study. Net Loss and Net Loss Per ShareThe Company recorded a net loss for the nine months ended September 30, 2025, of $102.1 million, compared to a net loss of $90.9 million for the nine months ended September 30, 2024. On a per share basis, net loss (based on the weighted average number of 124,723,638 shares outstanding over the period) was (0.82) USD/share for the nine months ended September 30, 2025. Cash and Cash EquivalentsOur Condensed Consolidated Financial Statements have been prepared assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Cash and cash equivalents amounted to $69.8 million as of September 30, 2025, compared to $32.5 million as of December 31, 2024, a net increase of $37.4 million. On March 27, 2025, the company announced a private placement financing (”2025 PIPE”) of up to $306.9 million (€284.5 million), to advance Viaskin® Peanut patch through Biologics License Application (”BLA”) submission and U.S. commercial launch, if approved. The 2025 PIPE included gross proceeds of $125.5 million (€116.3 million) received on April 7, 2025. However, it should be noted that the Company may receive an aggregate of up to $181.4 million (€168.2 million) in gross proceeds if all warrants in connection with the 2025 PIPE are exercised, subject to satisfaction of specified conditions. The VITESSE Phase 3 study hitting its primary endpoint will trigger an acceleration of the exercise period of the warrants (topline results are expected in the fourth quarter of 2025). DBV expects that the proceeds of this funding will be used for working capital and general corporate purposes, to finance the continued development of the Viaskin Peanut program in 4-7 years old, to finance the preparation and submission of a potential BLA, and to finance the readiness of a launch of Viaskin peanut in the U.S., if approved. In addition, in September 2025, the Company established an equity offering program (the “ATM Program”), pursuant to which the Company may offer and sell American Depositary Shares (”ADSs”), from time to time through its sale agent, having an aggregate offering price of up to $150.0 million (subject to French regulatory limits). Subsequent to the end of the third quarter, the Company received a total gross amount of approximately $30 million from the issuance of 11,538,460 Ordinary Shares (underlying 2,307,692 ADSs) on October 6, 2025 pursuant to the ATM Program. As of the date of the filing, with the receipt of the aforementioned proceeds, and based on its current operations, plans, and assumptions examined by the Board on October 28, 2025, the Company estimates that its cash and cash equivalents are sufficient to fund its operations into the third quarter of 2026. As such, cash and cash equivalents are not sufficient to fund operations for the next 12 months, and these conditions and events raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing financing options including additional sales under the ATM Program, potential warrant exercises, and strategic transactions. Our Condensed Consolidated Financial Statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company were unable to continue as a going concern. Given the Company’s historical operating losses and reliance on external financings, the Company may still seek additional capital for future needs through a combination of public or private equity or debt financings, collaborations, licensing agreements, and other funding options. While recent financing events have improved the Company’s financial position, access to additional capital in the future remains subject to market conditions and investor interest. Operating ActivitiesOur net cash flows used in operating activities were $86.0 million and $92.2 million during the nine months ended September 30, 2025 and 2024, respectively. Net cash flows used in operating activities decreased by $6.2 million as our costs and expenses have been contained and payment terms extended during the period covered by this report. Investing ActivitiesNet cash flows used in investing activities were $0.7 million and $1.5 million during the nine months ended September 30, 2025 and 2024, respectively. The variance is primarily explained by capitalized costs for the headquarters move to Châtillon. Financing ActivitiesNet cash flows from financing activities were $117.1 million for the nine months ended September 30, 2025 compared to $(88) thousand for the nine months ended September 30, 2024. This increase is due to the financing operation completed on April 7, 2025. CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION(unaudited) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Select Market (Ticker: DBVT – CUSIP: 23306J309). For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn. Forward-Looking StatementsThis press release may contain forward-looking statements and estimates, including statements regarding DBV’s financial condition, forecast of its cash runway, the therapeutic potential of Viaskin® Peanut patch and EPIT™. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 11, 2025, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 28, 2025, and as amended further by Amendment No. 2 on Form 10-K/A filed with the SEC on May 14, 2025, DBV’s Quarterly Report on Form 10-Q filed with the SEC on October 28, 2025, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release. Viaskin is a registered trademark of DBV Technologies. Investor ContactKatie MatthewsDBV Technologieskatie.matthews@dbv-technologies.com Media ContactBrett Whelan DBV Technologiesbrett.whelan@dbv-technologies.com Attachment

Financial StatementPhase 3Immunotherapy

18 Sep 2025

·dbv-technologies.com

DBV Technologies Announces Resignation of Board Member

Châtillon, France, September 18, 2025 DBV Technologies Announces Resignation of Board Member DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the resignation of Daniel Soland, as a member of its Board of Directors (the “Board”), effective immediately. “On behalf of the Board, DBV’s management team and shareholders, I thank Daniel for his commitment to the Company,” said Michel de Rosen, Chairman of the Board. “Since joining the Board in 2015, Daniel’s experience, insights and expertise have been invaluable to the Board and its Compensation Committee. We wish him continued success in his future endeavors.” “It has been a pleasure to serve on the Board and work with the DBV management team,” said Daniel Soland. “I look forward to watching the Company continue to advance the VIASKIN® Peanut patch and potentially bring a much needed treatment option to peanut allergic children and their families if approved.” The Board of Directors will continue to operate with its 9 remaining members and will evaluate with its Nomination and Governance Committee the appropriate timing and process for the provisional appointment of a new member to fill Mr. Soland’s vacancy, subject to ratification by the Company’s shareholders at the next Annual General Meeting. About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn. VIASKIN is a registered trademark of DBV Technologies. Investor Contact Katie MatthewsDBV Technologieskatie.matthews@dbv-technologies.com Media ContactBrett WhelanDBV Technologiesbrett.whelan@dbv-technologies.com Attachment

Executive ChangeImmunotherapy

100 Deals associated with Peanut allergy immunotherapy(DBV Technologies SA)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peanut Hypersensitivity	NDA/BLA	European Union	DBV Technologies SA	06 Nov 2020
Anaphylaxis	Phase 3	United States	DBV Technologies SA	24 Jun 2025
Anaphylaxis	Phase 3	Australia	DBV Technologies SA	24 Jun 2025
Anaphylaxis	Phase 3	Canada	DBV Technologies SA	24 Jun 2025
Anaphylaxis	Phase 3	United Kingdom	DBV Technologies SA	24 Jun 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02916446 (REALISE Study, Pubmed \| J Allergy Clin Immunol Pract)	Phase 3	Peanut Hypersensitivity	392	VIASKIN peanut patch 250 μg	nehkmguqht(nslkmcbghr) = fcziifubqa qkvonjpcdu (heeftpnkyv ) View more	Positive	01 May 2025
NCT03211247 (EPITOPE OLE, GlobeNewswire) Manual	Phase 3	Peanut Hypersensitivity	266	Viaskin Peanut (EPITOPE OLE)	hyccvoalel(beraudzwzg) = tegjuuoaub qwpybnwscz (zbeudnbamt ) View more	Positive	08 Jan 2025
				Placebo (EPITOPE OLE)	-
NCT03211247 (EPITOPE \| EPITOPE OLE, CTgov)	Phase 3	Peanut Hypersensitivity	414	Part B Viaskin Peanut 250 mcg (Part B Viaskin Peanut 250 mcg)	iqgirihjrc = znkvydzpbg dslrfntfos (iqqjmzdcgi, kkzbehpiwv - rgvbmvygux) View more	-	16 Dec 2024
				Part B Placebo (Part B Placebo)	iqgirihjrc = ugmkdvwxmz dslrfntfos (iqqjmzdcgi, itgqgxvtqt - spskgixbhn) View more
NCT01955109 (OLFUS-VIPES, CTgov)	Phase 2	Peanut Hypersensitivity	171	Viaskin Peanut (VIPES Initial Treatment Group: All Viaskin Peanut Doses)	stjuduytku = vzivsidkxi jibxsvubkz (bzitxvajpg, jgrmhqjfxp - awzjsotdrh) View more	-	30 Jun 2022
				Placebo (VIPES Initial Treatment Group: Placebo)	stjuduytku = yxfrqbsiol jibxsvubkz (bzitxvajpg, iqbvbhemet - bgoujjugne) View more
NCT03211247 (EPITOPE, GlobeNewswire) Manual	Phase 3	Peanut Hypersensitivity	362	Peanut allergy immunotherapy	kstdbhseub(inztlwgcgu) = ugnzwgbbcu kbegccosug (lffquufxaw ) View more	Positive	07 Jun 2022
				Placebo	kstdbhseub(inztlwgcgu) = omlffznqvo kbegccosug (lffquufxaw ) View more
REALISE (ACAAI2021)	Phase 3	Peanut Hypersensitivity skin-prick test \| peanut-specific IgE	393	Viaskin Peanut (VP250)	ygsyuwgkfz(odpcwjzduu) = 16 subjects experienced 17 anaphylactic reactions (none severe) deemed related to VP250 jruxfiymva (tzbxtjqryc ) View more	Positive	04 Nov 2021
NCT01675882 (VIPES, CTgov)	Phase 2	Peanut Hypersensitivity	221	Viaskin Peanut (Viaskin Peanut 50 μg)	dbtxtiltlt = ehbuegjntc tjtayopmcu (ailsoclpli, ltlitszxjl - blwyvpjoms) View more	-	27 Oct 2021
				Viaskin Peanut (Viaskin Peanut 100 μg)	dbtxtiltlt = iulujnkiww tjtayopmcu (ailsoclpli, qmedxmsuch - gbdbfygwsr) View more
REALISE (AAAAI2020)	Phase 3	Peanut Hypersensitivity peanut skin-prick test wheal diameter ≥8 mm \| peanut-specific IgE ≥14 kUA/L	393	Viaskin peanut 250 μg	btrvbqpmjl(iwxhymcryb) = idewacrjuj ynidemmqsx (bcplhagrlb ) View more	Positive	01 Feb 2020
				Placebo	btrvbqpmjl(iwxhymcryb) = agxsrcgmfc ynidemmqsx (bcplhagrlb ) View more
NCT01904604 (DAIT CoFAR6, CTgov)	Phase 2	Peanut Hypersensitivity	75	Placebo Viaskin® Patch (Placebo Patch)	xxzmljmryb = hiqwaatiaw ribaxbphgb (ioickizkkx, fsibkzhlnb - uhlvsfjneu) View more	-	26 Aug 2016
				DBV712 (100 µg Peanut Patch)	xxzmljmryb = ndgrzzjdwp ribaxbphgb (ioickizkkx, erocbpzpmn - fpprwyxvij) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Peanut allergy immunotherapy(DBV Technologies SA)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation